Shorted
Starpharma Holdings logo
SPL

Starpharma Holdings

Pharmaceuticals, Biotechnology & Life Sciences

Starpharma Holdings is an Australian biotechnology company focused on developing dendrimer technology for pharmaceutical and life science applications. Their proprietary dendrimer platform is used to improve drug delivery, enhance drug efficacy, and create new pharmaceutical products. The company's market position is built on its innovative technology and partnerships with pharmaceutical companies.

Short position

short percentage0.03%
reported shorts150K
shares on issue479.739M

Starpharma Holdings (ASX:SPL) has 0.03% of its shares on issue reported as short positions as of 5 Oct 2026, or about 150,000 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.08 percentage points. Its highest recorded short interest was 5.92% in September 2013. SPL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Starpharma Holdings (SPL) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
15 Sept

Starpharma Announces 2026 Annual General Meeting for November 6

Starpharma (ASX:SPL), a biotechnology firm specializing in dendrimer technology, has confirmed that its 2026 Annual General Meeting (AGM) will take place on Friday, 6 November 2026. The Notice of Meeting is expected to be released in early October. Key Points Starpharma's 2026 AGM is set for Friday, 6 November 2026. Director nomination submissions close on Friday, 18 September 2026, at 5:00pm AEST. The company acknowledged a delayed filing under ASX Listing Rule 3.13.1 due to an administrativ...

Continue reading
Kalkine
Neutral
27 Aug

How Did Starpharma (ASX:SPL) Shift the Healthcare Stocks View?

Highlights Reporting season has put Starpharma (ASX:SPL) back into the Australian market conversation, with the full-year update offering a fresh test of clinical demand, reimbursement and execution. Within the broader market backdrop, the more useful reading will come from how the business addresses patient volumes, product adoption, regulatory pathways and operating leverage. The next useful checkpoint for Starpharma is whether its latest disclosure adds clearer evidence on execution, operati...

Continue reading
Kalkine
Neutral
27 Aug

Is Starpharma (ASX:SPL) Shaping a New Cannabis Stocks View?

Highlights Reporting season has put Starpharma (ASX:SPL) back into the Australian market conversation, with the full-year update offering a fresh test of regulatory access, product mix and distribution. Within the [All Ordinaries] backdrop, the more useful reading will come from how the business addresses market access, portfolio breadth, manufacturing discipline and channel economics. The next useful checkpoint for Starpharma is whether its latest disclosure adds clearer evidence on execution,...

Continue reading
Kalkine
Neutral
21 Aug

Starpharma Holdings (ASX:SPL): Why Insider Confidence Is Turning Heads

Highlights Starpharma Holdings is drawing attention after strong insider accumulation alongside robust earnings and revenue expectations. Several Australian growth companies with notable insider ownership continue to stand out despite broader market volatility. Healthcare, aged care and mining businesses remain in focus as market conditions shift. Australia's share market continues to navigate a cautious environment as global developments, including stronger oil prices and geopolitical u...

Continue reading
Kalkine
Neutral
21 July

UBS Group AG Ends Substantial Shareholding in StarPharma Holdings Limited as of July 2026

UBS Group AG along with its associated corporate entities officially ceased to be a substantial shareholder in StarPharma Holdings Limited (ASX: SPL) on 17 July 2026, as disclosed in a Form 605 notice submitted to the company. Between 22 and 24 June 2026, UBS executed a series of buy and sell transactions involving ordinary shares of the Australian biopharmaceutical firm, resulting in its relevant interest falling below the substantial holding threshold. This marks a notable shift in the shareho...

Continue reading